Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from CASI Pharmaceuticals ( (CASI) ) is now available.
On August 29, 2025, CASI Pharmaceuticals announced its second quarter business and financial results, highlighting a strategic pivot towards developing its CID-103 program, which has received FDA clearance for a Phase 1 study in renal allograft antibody-mediated rejection. The company is also conducting a Phase 1/2 study for CID-103 in immune thrombocytopenic purpura. Additionally, CASI entered an agreement to sell its equity interests and rights related to certain products in China to Kaixin Pharmaceuticals for $20 million, a move aimed at focusing resources on core priorities. Financially, CASI reported a 5% increase in revenue to $4.2 million for the quarter, but also a significant net loss of $13.4 million, reflecting increased research, development, and marketing expenses.
The most recent analyst rating on (CASI) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on CASI Pharmaceuticals stock, see the CASI Stock Forecast page.
Spark’s Take on CASI Stock
According to Spark, TipRanks’ AI Analyst, CASI is a Neutral.
CASI Pharmaceuticals’ overall stock score is primarily impacted by its weak financial performance, characterized by declining revenue and high leverage. Technical analysis provides some neutral signals, but the valuation remains unattractive due to negative earnings. The absence of earnings call data and corporate events limits additional insights.
To see Spark’s full report on CASI stock, click here.
More about CASI Pharmaceuticals
CASI Pharmaceuticals, Inc. is a publicly-traded biopharmaceutical company focused on developing CID-103, an anti-CD38 monoclonal antibody for organ transplant rejection and autoimmune diseases. CID-103 is a fully human IgG1, potentially best-in-class, clinical stage, anti-CD38 monoclonal antibody, and CASI owns exclusive global rights to it.
Average Trading Volume: 1,307,036
Technical Sentiment Signal: Hold
Current Market Cap: $37.8M
Learn more about CASI stock on TipRanks’ Stock Analysis page.